by Intelligent AI, ML Algorithms Supporting COVID-19 Molecular Applications
The AI (Artificial Intelligence)-driven COVID-19 drug discovery is gaining increased popularity in the respiratory virus infection drugs market. Since the coronavirus has become an international health concern, there has been an unprecedented demand for drugs and vaccines. As such, AI holds promising potentials in quick identification of COVID-19 drugs. Thus, companies in the respiratory virus infection drugs market are collaborating with scientists and researchers to predict drugs and peptides that can be used as therapeutic medication for coronavirus treatment.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111830
Pharmaceutical companies are increasing efforts to predict drugs directly from the sequences of infected patients, since they have a better affinity with the target. However, companies need to accelerate their testing capabilities in order to verify safety and feasibility to combat COVID-19. Intelligent algorithms based on machine learning (ML) and Big Data are supporting molecular applications.
Rise in R&D Helps Address Low Solubility of Favipiravir in Aqueous Media
The respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.
Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.
Efficient Drug Delivery via Nanotechnology Offers Growth Prospects in Clinical Practice
Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.
Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.
AI-based Multi-program Approach Enables Development of Successful Candidates for Antibiotic Resistance
The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.
In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.
State-of-art DAAs Holds Promising Potentials for RSV Treatment
The respiratory syncytial virus (RSV) is being associated with limited treatment options, resulting in millions of hospitalizations per year. Palivizumab, a monoclonal antibody, is considered as the gold standard for prophylaxis in high-risk infants. However, palivizumab and ribavirin are prone to limited efficacy and significant safety concerns. Hence, manufacturers in the respiratory virus infection drugs market are increasing their research in direct acting antiviral agents (DAAs) to target key steps in the viral life cycle.
It has been found that DAAs are producing landmark clinical studies, which involve nucleoside inhibitors. On the other hand, non-nucleoside inhibitors of replication are being reviewed in addition to inhibitors of other mechanisms. As such, pharma companies in the respiratory virus infection drugs market are taking giant strides in R&D pertaining to viral proteins or host cell factors for inhibition of viral replication.
Companies Forge Strategic Partnerships to Innovate in Treatment for LRTI in Infants
In vitro and in vivo model systems of the RSV disease are being highlighted in order to create novel drug targets. Companies in the respiratory virus infection drugs market are expanding their treatment options for lower respiratory tract infections (LRTI). For instance, Sanofi— a global biopharmaceutical company, announced that it received positive Phase 2b trial for nirsevimab, since it showed significant decline in medically attended lower respiratory tract infections. This involves increased hospitalization caused due to RSV in healthy preterm infants.
Single dose monoclonal antibodies are found to significantly reduce medically attended RSV LRTI infants through the full RSV season. Nirsevimad is being highly publicized as an extended half-life RSV monoclonal antibody. Companies are entering into strategic partnerships to innovate in treatments for LRTI in infants. Nirsevimab is gaining popularity as the new standard of care by offering innovative immunization for immediate and sustained protection for all infants during the first season of RSV.
Favipiravir and Boloxavir Approved for Influenza Treatment in Japan
Companies in the respiratory virus infection drugs market are increasing their production capabilities for anti-influenza drugs. Pharma companies in the respiratory virus infection drugs market are developing inhibitors of influenza virus polymerase, which are among the most promising types of drugs. Favipiravir and boloxavir are being approved for influenza treatment in Japan and the U.S. It has been found that favipiravir effectively and selectively inhibits the RNA dependent RNA polymerase of RNA viruses.
Analysts’ Viewpoint
Sustainable pharmaceutical innovations in COVID-19 treatment hold promising potentials for other infectious diseases. Thus, the respiratory virus infection drugs market is estimated to grow at a healthy CAGR of ~7% during the assessment period. However, the issue of drug resistance in case of constant mutation of influenza virus is impacting market growth. Hence, pharma companies should conduct a sustained surveillance of the drug susceptibility of influenza viruses. Moreover, limited efficacy of influenza vaccines and drug resistance from small molecule antiviral drugs have led to the demand for new antivirals with novel mode of action.
Respiratory Virus Infection Drugs Market: Overview
According to Transparency Market Research’s latest report on the global respiratory virus infection drugs market for the historical period 2018–2019 and forecast period of 2020–2030, increase in focus on research & development is projected to drive the global respiratory virus infection drugs market
According to the report, the global respiratory virus infection drugs market was valued over US$ 38.6 Bn in 2019 and is anticipated to expand at a CAGR of ~7% from 2020 to 2030
Respiratory virus infection is a type of infection of the airway and lungs caused by different types of virus. Viral respiratory infections (VRIs) include cold, flu, and bronchiolitis. Several medications are used for the treatment of respiratory virus infections including prescription and OTC.
Surge in Adoption of Combination Therapy to Drive Respiratory Virus Infection Drugs Market
Adoption of combination therapy is increasing, as it is more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.
Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory diseases such as asthma and COPD
Steady rise in prevalence of respiratory virus infections across the globe leads to high demand for advanced therapeutics. This, in turn, is expected to propel the global respiratory virus infection drugs market.
Increase in Expenditure on Healthcare and Immunization Augments Respiratory Virus Infection Drugs Market
Rise in healthcare expenditure increases the availability of better healthcare infrastructure, improves operational efficiency, and encourages awareness programs related to vaccination and treatment of diseases
According to the World Health Organization, expenditure on immunization in 72 countries across the globe increased between 2005 and 2015. According to the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. in 2017 was 17.9% of the GDP.
Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Market
Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. It hampers the revenue generated from the sale of branded drugs and can affect the market share of a company. This, in turn, is likely to hamper the growth of the global respiratory virus infection drugs market.
For instance, AstraZeneca’s Symbicort Turbuhaler went off-patent in Europe in 2019, whereas, GlaxoSmithKline plc’s Qvar, Singulair, and Diskus device patents have expired. This is projected to lead to dramatic decline in sales, thereby affecting market positions of the companies.
Respiratory Virus Infection Drugs Market: Competition Landscape
This report profiles major players operating in the global respiratory virus infection drugs market based on various attributes and recent developments
The global respiratory virus infection drugs market is highly fragmented, with the presence of large number of global as well as regional players
Leading players operating in the global respiratory virus infection drugs market include
- GlaxoSmithKline plc
- Merck & Co., Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Cipla, Inc.
- CHIESI Farmaceutici S.p.A.
- Orion Corporation
Key Questions Answered in Respiratory Virus Infection Drugs Market Report
- What is the scope of growth for product companies in the global respiratory virus infection drugs market?
- What will be the Y-o-Y growth of the global respiratory virus infection drugs market between 2020 and 2030?
- What is the influence of changing trends in technologies on the global respiratory virus infection drugs market?
- Will North America continue to be the most profitable market for respiratory virus infection drugs?
- Which factors are anticipated to hamper the global respiratory virus infection drugs market during the forecast period?
- Which are the leading companies in the global respiratory virus infection drugs market?
Respiratory Virus Infection Drugs Market – Segmentation
Drug Type
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Cough Suppressants
- Nasal Decongestants
- Others
Infection Type
- Respiratory Syncytial Virus (RSV) Infection
- Influenza Virus Infection
- Parainfluenza Virus Infection
- Adenovirus Infection
- Rhinovirus Infection
- Others
Route of Administration
- Oral
- Parenteral
Mode of Purchase
- Prescription-based Drugs
- Over-the-counter Drugs
Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Clinics
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111830/2900
